Oncolytics Biotech Inc. (ONC.TO)
CAD 0.75
(-3.85%)
CAD 0.75
(-3.85%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 38.82 Million CAD | 3.98% |
| 2022 | 37.33 Million CAD | -18.63% |
| 2021 | 45.88 Million CAD | 33.58% |
| 2020 | 34.34 Million CAD | 74.72% |
| 2019 | 19.65 Million CAD | 32.24% |
| 2018 | 14.86 Million CAD | -18.1% |
| 2017 | 18.15 Million CAD | 22.98% |
| 2016 | 14.75 Million CAD | -46.11% |
| 2015 | 27.38 Million CAD | 59.27% |
| 2014 | 17.19 Million CAD | -39.08% |
| 2013 | 28.22 Million CAD | 27.83% |
| 2012 | 22.07 Million CAD | -38.71% |
| 2011 | 36.02 Million CAD | -18.92% |
| 2010 | 44.43 Million CAD | 19.22% |
| 2009 | 37.26 Million CAD | 166.46% |
| 2008 | 13.98 Million CAD | -54.56% |
| 2007 | 30.78 Million CAD | -8.29% |
| 2006 | 33.56 Million CAD | -27.5% |
| 2005 | 46.29 Million CAD | 17.23% |
| 2004 | 39.48 Million CAD | 51.58% |
| 2003 | 26.05 Million CAD | 44.98% |
| 2002 | 17.96 Million CAD | -5.79% |
| 2001 | 19.07 Million CAD | -11.94% |
| 2000 | 21.65 Million CAD | 202.33% |
| 1999 | 7.16 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 34.75 Million CAD | -10.48% |
| 2024 Q2 | 32.06 Million CAD | -7.72% |
| 2023 Q1 | 35.32 Million CAD | -5.37% |
| 2023 FY | 38.82 Million CAD | 3.98% |
| 2023 Q4 | 38.82 Million CAD | -15.77% |
| 2023 Q3 | 46.08 Million CAD | 44.18% |
| 2023 Q2 | 31.96 Million CAD | -9.52% |
| 2022 Q4 | 37.33 Million CAD | -4.17% |
| 2022 Q1 | 44.44 Million CAD | -3.13% |
| 2022 Q2 | 40.23 Million CAD | -9.47% |
| 2022 FY | 37.33 Million CAD | -18.63% |
| 2022 Q3 | 38.95 Million CAD | -3.18% |
| 2021 Q1 | 54.18 Million CAD | 57.75% |
| 2021 Q2 | 56.3 Million CAD | 3.93% |
| 2021 Q3 | 52.59 Million CAD | -6.6% |
| 2021 Q4 | 45.88 Million CAD | -12.76% |
| 2021 FY | 45.88 Million CAD | 33.58% |
| 2020 FY | 34.34 Million CAD | 74.72% |
| 2020 Q4 | 34.34 Million CAD | 9.94% |
| 2020 Q2 | 34.6 Million CAD | 0.15% |
| 2020 Q3 | 31.24 Million CAD | -9.72% |
| 2020 Q1 | 34.55 Million CAD | 75.77% |
| 2019 Q1 | 16.46 Million CAD | 10.74% |
| 2019 Q3 | 16.28 Million CAD | 6.42% |
| 2019 Q4 | 19.65 Million CAD | 20.71% |
| 2019 FY | 19.65 Million CAD | 32.24% |
| 2019 Q2 | 15.3 Million CAD | -7.04% |
| 2018 Q1 | 14.12 Million CAD | -22.17% |
| 2018 FY | 14.86 Million CAD | -18.1% |
| 2018 Q4 | 14.86 Million CAD | -18.1% |
| 2018 Q3 | 18.14 Million CAD | -12.29% |
| 2018 Q2 | 20.69 Million CAD | 46.48% |
| 2017 Q3 | 14.84 Million CAD | -15.53% |
| 2017 FY | 18.15 Million CAD | 22.98% |
| 2017 Q1 | 10.62 Million CAD | -28.02% |
| 2017 Q4 | 18.15 Million CAD | 22.24% |
| 2017 Q2 | 17.57 Million CAD | 65.47% |
| 2016 Q1 | 23.02 Million CAD | -15.93% |
| 2016 Q2 | 21.36 Million CAD | -7.19% |
| 2016 Q3 | 18.43 Million CAD | -13.71% |
| 2016 Q4 | 14.75 Million CAD | -19.95% |
| 2016 FY | 14.75 Million CAD | -46.11% |
| 2015 Q4 | 27.38 Million CAD | -11.67% |
| 2015 Q1 | 31.44 Million CAD | 82.89% |
| 2015 FY | 27.38 Million CAD | 59.27% |
| 2015 Q3 | 31 Million CAD | -6.6% |
| 2015 Q2 | 33.18 Million CAD | 5.55% |
| 2014 Q4 | 17.19 Million CAD | -4.9% |
| 2014 Q2 | 20.04 Million CAD | -12.98% |
| 2014 Q1 | 23.03 Million CAD | -18.38% |
| 2014 FY | 17.19 Million CAD | -39.08% |
| 2014 Q3 | 18.07 Million CAD | -9.82% |
| 2013 Q2 | 39.26 Million CAD | -11.31% |
| 2013 Q1 | 44.27 Million CAD | 100.53% |
| 2013 Q4 | 28.22 Million CAD | -13.29% |
| 2013 Q3 | 32.54 Million CAD | -17.11% |
| 2013 FY | 28.22 Million CAD | 27.83% |
| 2012 Q1 | 47.37 Million CAD | 31.5% |
| 2012 Q4 | 22.07 Million CAD | -24.09% |
| 2012 FY | 22.07 Million CAD | -38.71% |
| 2012 Q2 | 36.98 Million CAD | -21.92% |
| 2012 Q3 | 29.08 Million CAD | -21.37% |
| 2011 Q1 | 54.94 Million CAD | 23.66% |
| 2011 FY | 36.02 Million CAD | -18.92% |
| 2011 Q4 | 36.02 Million CAD | -16.32% |
| 2011 Q3 | 43.05 Million CAD | -13.36% |
| 2011 Q2 | 49.69 Million CAD | -9.56% |
| 2010 Q2 | 26.56 Million CAD | -11.9% |
| 2010 Q3 | 21.13 Million CAD | -20.45% |
| 2010 Q4 | 44.43 Million CAD | 110.21% |
| 2010 FY | 44.43 Million CAD | 19.22% |
| 2010 Q1 | 30.15 Million CAD | -15.27% |
| 2009 Q2 | 12.75 Million CAD | 30.13% |
| 2009 FY | 37.26 Million CAD | 166.46% |
| 2009 Q4 | 35.59 Million CAD | 247.59% |
| 2009 Q3 | 10.23 Million CAD | -19.72% |
| 2009 Q1 | 9.8 Million CAD | -29.92% |
| 2008 Q3 | 13.54 Million CAD | -28.77% |
| 2008 FY | 13.98 Million CAD | -54.56% |
| 2008 Q1 | 27.4 Million CAD | -10.96% |
| 2008 Q2 | 19.01 Million CAD | -30.64% |
| 2008 Q4 | 13.98 Million CAD | 3.28% |
| 2007 Q2 | 37.69 Million CAD | -9.76% |
| 2007 Q3 | 33.89 Million CAD | -10.09% |
| 2007 FY | 30.78 Million CAD | -8.29% |
| 2007 Q1 | 41.77 Million CAD | 24.46% |
| 2007 Q4 | 30.78 Million CAD | -9.19% |
| 2006 Q2 | 40.82 Million CAD | -6.49% |
| 2006 FY | 33.56 Million CAD | -27.5% |
| 2006 Q4 | 33.56 Million CAD | -11.62% |
| 2006 Q3 | 37.98 Million CAD | -6.98% |
| 2006 Q1 | 43.66 Million CAD | -5.69% |
| 2005 Q1 | 40.51 Million CAD | 2.61% |
| 2005 Q3 | 40.11 Million CAD | 5.34% |
| 2005 Q2 | 38.08 Million CAD | -6.02% |
| 2005 Q4 | 46.29 Million CAD | 15.41% |
| 2005 FY | 46.29 Million CAD | 17.23% |
| 2004 Q1 | 25.43 Million CAD | -2.36% |
| 2004 Q2 | 31.22 Million CAD | 22.75% |
| 2004 Q3 | 29.47 Million CAD | -5.6% |
| 2004 Q4 | 39.48 Million CAD | 33.99% |
| 2004 FY | 39.48 Million CAD | 51.58% |
| 2003 Q1 | 16.7 Million CAD | -7.05% |
| 2003 Q2 | 18.81 Million CAD | 12.65% |
| 2003 Q3 | 21.53 Million CAD | 14.44% |
| 2003 Q4 | 26.05 Million CAD | 20.99% |
| 2003 FY | 26.05 Million CAD | 44.98% |
| 2002 Q1 | 16.26 Million CAD | -14.74% |
| 2002 Q3 | 17.33 Million CAD | -10.98% |
| 2002 Q4 | 17.96 Million CAD | 3.68% |
| 2002 FY | 17.96 Million CAD | -5.79% |
| 2002 Q2 | 19.46 Million CAD | 19.71% |
| 2001 FY | 19.07 Million CAD | -11.94% |
| 2001 Q1 | 20.94 Million CAD | -3.29% |
| 2001 Q4 | 19.07 Million CAD | -4.63% |
| 2001 Q2 | 20.72 Million CAD | -1.06% |
| 2001 Q3 | 19.99 Million CAD | -3.49% |
| 2000 Q4 | 21.65 Million CAD | -4.87% |
| 2000 Q2 | 21.19 Million CAD | -0.98% |
| 2000 FY | 21.65 Million CAD | 202.33% |
| 2000 Q1 | 21.4 Million CAD | 0.0% |
| 2000 Q3 | 22.76 Million CAD | 7.41% |
| 1999 FY | 7.16 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | -2504.665% |
| Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | -45.268% |
| Helix BioPharma Corp. | 1.48 Million CAD | -2507.119% |
| Microbix Biosystems Inc. | 35.65 Million CAD | -8.883% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | -102.885% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 12.366% |
| Sernova Corp. | 22.1 Million CAD | -75.602% |